Skip to search formSkip to main contentSkip to account menu

everolimus 5 MG Tablet for Oral Suspension [Afinitor]

Known as: Afinitor Disperz 5 MG Tablet for Oral Suspension, EVEROLIMUS 5 mg ORAL TABLET, FOR SUSPENSION [Afinitor Disperz] 
National Institutes of Health

Related topics

Related topics

9 relations
Butylated HydroxytolueneCrospovidoneLactose MonohydrateMagnesium stearate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Neue Therapieoptionen bei Neuroendokrinen Tumoren des Gastrointestinaltraktes
Recent therapy options of gastro- intestinal neuroendocrine tumours. Neuroen- docrine tumors (NET) of gastroenteropancreatic (GEP… 
Review
2016
Review
2016
Problems of diagnostic assessment in advanced pancreatic neuroendocrine neoplasm and treatment implications: a case report and literature review.
We are reporting a case of a 55-year-old woman who was diagnosed as having a non-functioning pancreatic neuroendocrine neoplasm… 
2012
2012
FDA Approves Everolimus (Afinitor Disperz) for Rare Pediatric Brain Tumor
The FDA approved a dissolvable form of everolimus (Afinitor Disperz) for the treatment of children with subependymal giant cell… 
2012
2012
Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2-negative locally advanced or metastatic breast cancer who are…
In Austria, about 24% of women with initially diagnosed breast cancer (BC) have locally advanced and about 5% have metastatic… 
Review
2012
Review
2012
Signalling Pathways Passing Src in Pancreatic Endocrine Tumours: Relevance for Possible Combined Targeted Therapies
The most frequent molecular abnormalities in pancreatic endocrine tumours (PETs) are mutations of the MEN1 gene, deregulation of… 
Review
2010
Review
2010
Everolimus in renal cell carcinoma.
Everolimus (also known as RAD-001; Afinitor®) is an orally active inhibitor of the intracellular protein kinase mammalian target… 
2009
2009
Everolimus (Afinitor®), Trastuzumab (H), and Paclitaxel (P) or Vinorelbine (V) in the Treatment of HER-2+ Metastatic Breast Cancer (MBC) Patients (Pts) Pre-Treated with Lapatinib-Containing Therapy…
Introduction: The re-introduction of H-based therapy after progression on a lapatinib-containing regimen has not yet been… 
2009
2009
Everolimus (Afinitor®) for advanced/metastatic kidney cancer
The purpose of this report was to evaluate efficacy and safety of second-line therapy with everolimus, an mTOR inhibitor, for the… 
Review
2009
Review
2009
Aktuelles zur Systemtherapie des metastasierten Nierenzellkarzinoms
ZusammenfassungDie letzten 5 Jahre waren durch grundlegende Veränderungen in der Systemtherapie des metastasierten… 
2009
2009
Non-Infectious Pneumonitis (NIP) in Breast Cancer (BC) Patients (Pts) Treated with Everolimus (Afinitor™) Containing Therapy: Analysis of Five Studies.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)